NEW YORK (360Dx) – BioMérieux said this week that its net income for the year was €179.2 million ($189.1 million), or €4.54 per share, up from €110.3 million, or €2.80 per share in 2015. For 2016, its R&D expenses were down 5 percent year-over-year to €238.9 million from €243.6 million. Its SG&A expenses were €529.2 million, up 4 percent from €510.8 million in 2015.

BioMérieux announced additional 2016 financial results in January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.